Date: 2016-07-08
Type of information: Nomination
Compound:
Company: Horama (France)
Therapeutic area: Rare diseases - Genetic diseases - Ophtalmological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 8, 2016, Horama announced the appointment of Christine Placet to the post of Director General. Created in 2014, Horama is a clinical stage developer of gene therapy treatments based vectors derived from a recombinant adeno-associated virus (rAAV) and targeting of rare diseases of the retina. The portfolio of the company includes a product in clinical and two products that come into clinic in the coming months. Christine Placet will bolster the Horama management team and also incorporates the Board of Directors of the company. Before joining Horama, Christine was President and CEO of Trophos , a pharmaceutical company specializing in clinical stage development of an innovative treatment for spinal muscular atrophy. After a positive clinical study phase 2/3, the company was sold to Roche for early 2015 amounting to €470 million euros.
Financial terms:
Latest news:
